Relative dose intensity delivered to patients with early breast cancer: Canadian experience

Current Oncology

Volumn 16, Issue 6, 2009, Pages 8-12

  Raza, S ^b   Welch, S ^b   Younus, Jawaid ^a  

^a LONDON REGIONAL CANCER PROGRAM   (Canada)

^b NONE

Author keywords

Adjuvant chemotherapy; Early breast cancer; Relative dose intensity

Indexed keywords

CYCLOPHOSPHAMIDE; DOCETAXEL; DOXORUBICIN; EPIRUBICIN; FLUOROURACIL; GRANULOCYTE COLONY STIMULATING FACTOR; PACLITAXEL;

ADJUVANT THERAPY; ADULT; ARTICLE; BREAST CANCER; CANADA; CANCER CENTER; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; ELDERLY CARE; FEBRILE NEUTROPENIA; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; POSTMENOPAUSE; PREMENOPAUSE; RADIATION DOSE;

EID: 72949105770     PISSN: None     EISSN: 17187729     Source Type: Journal    
DOI: None     Document Type: Article

References (16)

1. Canadian Cancer Society and the National Cancer Institute of Canada. Canadian Cancer Statistics 2006. Toronto: Canadian Cancer Society; 2006.
2. Early Breast Cancer Trialists' Collaborative Group (EBCTCG). Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomized trials. Lancet 2005;365:1687-1717
3. Bonadonna G, Valagussa P, Moliterni A, Zambetti M, Brambilla C. Adjuvant cyclophosphamide, methotrexate, and fluorouracil in node-positive breast cancer: the results of 20 years of follow-up. N Engl J Med 1995;332:901-906
4. Kwak LW, Halpern J, Olshen RA, Horning SJ. Prognostic significance of actual dose intensity in diffuse large-cell lymphoma: results of a tree-structured survival analysis. J Clin Oncol 1990;8:963-977 (Pubitemid 20200184)
5. Lepage E, Gisselbrecht C, Haioun C, et al. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA (Groupe d'Etude des Lymphomes de l'Adulte). Ann Oncol 1993;4:651-656
6. Lyman GH, Dale DC, Crawford J. Incidence and predictors of low dose-intensity in adjuvant breast cancer chemotherapy: a nationwide study of community practices. J Clin Oncol 2003;21:4524-4531 (Pubitemid 46594022)
7. Lyman GH, Dale DC, Friedberg J, Crawford J, Fisher RI. Incidence and predictors of low chemotherapy dose-intensity in aggressive non-Hodgkin's lymphoma: a nationwide study. J Clin Oncol 2004;22:4302-4311 (Pubitemid 41185151)
8. Wood WC, Budman DR, Korzun AH, et al. Dose and dose intensity of adjuvant chemotherapy for stage II, node-positive breast carcinoma. N Engl J Med 1994;330:1253-1259 (Pubitemid 24129957)
9. Mamounas EP, Bryant J, Lembersky B, et al. Paclitaxel after doxorubicin plus cyclophosphamide as adjuvant chemotherapy for node-positive breast cancer: results from NSABP B-28. J Clin Oncol 2005;23:3686-3696 (Pubitemid 46252463)
10. Roché H, Fumoleau P, Spielmann M, et al. Sequential adjuvant epirubicin-based and docetaxel chemotherapy for node-positive breast cancer patients: the FNCLCC pacs 01 Trial. J Clin Oncol 2006;24:5664-5671 (Pubitemid 46631307)
11. Bonneterre J, Roché H, Kerbrat P, et al. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial. J Clin Oncol 2005;23:2686-2693
12. Hryniuk W, Frei E 3rd, Wright FA. A single scale of comparing dose intensity of all chemotherapy regimens in breast cancer: summation dose intensity. J Clin Oncol 1998;16:3137-3147
13. Mayers C, Panzarella T, Tannock IF. Analysis of prognostic effects of inclusion in a clinical trial and of myelosuppression on survival after adjuvant chemotherapy for breast carcinoma. Cancer 2001;91:2246-2257
14. Shayne M, Crawford J, Dale DC, Culakova E, Lyman GH. Predictors of reduced dose intensity in patients with early stage breast cancer receiving adjuvant chemotherapy. Breast Cancer Res Treat 2006;100:255-262
15. Skipper HE. Kinetics of mammary tumor cell growth and implications for therapy. Cancer 1971;28:1479-1499
16. Smith TJ, Khatcheressian J, Lyman GH, et al. 2006 Update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol 2006;24:3187-3205